0001380106-24-000162.txt : 20240802 0001380106-24-000162.hdr.sgml : 20240802 20240802070228 ACCESSION NUMBER: 0001380106-24-000162 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240802 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240802 DATE AS OF CHANGE: 20240802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RAPID MICRO BIOSYSTEMS, INC. CENTRAL INDEX KEY: 0001380106 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 208121647 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40592 FILM NUMBER: 241168821 BUSINESS ADDRESS: STREET 1: 25 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 978-349-3200 MAIL ADDRESS: STREET 1: 25 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RAPID MICRO BIOSYSTEMS INC DATE OF NAME CHANGE: 20061103 8-K 1 rpid-20240802.htm 8-K rpid-20240802
0001380106false00013801062024-08-022024-08-020001380106dei:FormerAddressMember2024-08-022024-08-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 2, 2024
RAPID MICRO BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4059220-8121647
(State or other jurisdiction
of incorporation or organization)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
 25 Hartwell Avenue, Lexington, MA
02421
(Address of principal executive offices)
(Zip Code)
978-349-3200
(Registrant’s telephone number, including area code)

1001 Pawtucket Boulevard West, Suite 280, Lowell, MA 01854
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbols		Name of each exchange on which
registered
Class A Common Stock, $0.01 par value per shareRPIDThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




Item 2.02    Results of Operations and Financial Condition.

On August 2, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its unaudited financial results for its second quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.


Item 3.01    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed, on February 2, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for its Class A common stock, par value $0.01 per share (the “common stock”), had closed below $1.00 per share for the preceding thirty (30) consecutive business days (December 18, 2023 through February 1, 2024) and that, as a result, the Company was not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(2) (the “Bid Price Requirement”). To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 or higher for a minimum of ten consecutive business days, though Nasdaq has the discretion to extend the ten business day period to up to twenty (20) consecutive business days.
The initial period during which the Company was required to regain compliance with the Bid Price Requirement expired on July 31, 2024. Because the Company did not regain compliance with the requirement during the initial period, the Company will transfer the listing of its common stock to the Nasdaq Capital Market, effective at the opening of business on August 5, 2024, in order to secure an additional 180 calendar day compliance period ending on January 27, 2025 (the “Second Compliance Period”). As a condition of securing the Second Compliance Period, the Company informed Nasdaq that it intends to regain compliance with the Bid Price Requirement during the Second Compliance Period, which may include the implementation of a reverse stock split if necessary. The Company intends to monitor the closing bid price of its common stock and take reasonable measures to regain compliance with the Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement even during the Second Compliance Period, nor can there be any assurance that the Company will receive the necessary approvals from its stockholders to effect a reverse stock split. If the Company does not cure the deficiency during the Second Compliance Period and regain compliance with the Bid Price Requirement by January 27, 2025, Nasdaq will provide written notice that the Company's common stock will be subject to delisting. In the event of such notification, the Company may appeal Nasdaq’s delisting determination. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq, such appeal would be successful. As a result, there can be no assurance that the Company will be able to continue the listing of its common stock on the Nasdaq Capital Market.

Item 9.01    Financial Statements and Exhibits.
(d)Exhibits.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance for full year 2024 revenue, system placements and gross margins; the Company's operational efficiency program, including the expected costs, timing, savings and other intended benefits thereof; the Company's expectations for achieving positive cash flow by the end of 2027 without additional financing; the Company’s ability to drive substantial shareholder value; the Company's financial


position and cash runway; expected placements of Growth Direct systems, the anticipated timing of such placements and the impact on the Company’s revenue; and intentions regarding the Company’s commercial execution and improvements to gross margins.

In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the Company’s ability to implement and realize the intended benefits of its operational efficiency program; the Company's ability to achieve positive cash flow without requiring additional financing; the impact of the operation efficiency programs on the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this Current Report on Form 8-K to reflect changes since the date of this Current Report on Form 8-K, except as may be required by law.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAPID MICRO BIOSYSTEMS, INC.
Date: August 2, 2024By:/s/ Sean Wirtjes
Sean Wirtjes
Chief Financial Officer

 EX-99.1 2 rpid-20240630xexx991x20240.htm EX-99.1 Document


Exhibit 99.1
Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results
•Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023
•150th Growth Direct® system placed with an existing top 15 global pharma customer
•First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customer
•Gross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to the first quarter of 2024
•Announces operational efficiency program that is expected to enable the Company to achieve positive cash flow without additional financing
•Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023

Lexington, MA, August 2, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2024.
"Through the first half of 2024, we have been executing well and advancing our strategic priorities of accelerating Growth Direct® system placements, meaningfully improving gross margins and commercializing Growth Direct Rapid Sterility,” said Robert Spignesi, President and CEO. “This morning, we announced an operational efficiency program that is expected to enable the Company to achieve positive cash flow without additional financing. We believe the combination of our demonstrated consistent business performance, coupled with disciplined cash management, will allow us to drive substantial shareholder value.”
Second Quarter Financial Results
Total revenue for the second quarter of 2024 increased 32.3% to $6.6 million compared to $5.0 million in the second quarter of 2023. The Company placed five new Growth Direct® systems and completed the validation of five customer systems compared to two placements and three validations in the second quarter of 2023. Product revenue increased by 43.2% to $4.5 million, compared to $3.2 million in the second quarter of 2023. Service revenue increased by 13.5% to $2.1 million, compared to $1.8 million in the second quarter of 2023. Recurring revenue increased by 7.0% to $3.8 million, compared to $3.6 million in the second quarter of 2023.
Total cost of revenue was $6.8 million in the second quarter of 2024, compared to $6.9 million in the second quarter of 2023.
Total operating expenses were $13.2 million in the second quarter of 2024, essentially flat compared to the prior year. General and administrative expenses decreased by 13.5% compared to the second quarter of 2023. Research and development and sales and marketing expenses increased by 15.8% and 13.3%, respectively, in the second quarter of 2024 compared to the second quarter of 2023.



Net loss for the second quarter of 2024 was $12.6 million, compared to $14.0 million in the second quarter of 2023. Net loss per share for the second quarter of 2024 was $0.29, compared to $0.33 in the second quarter of 2023.
Cash, cash equivalents and investments were approximately $70 million, and the Company had no debt outstanding as of June 30, 2024.

Operational Efficiency Program

In July 2024, the Company completed an enterprise-wide review of opportunities to realize operational efficiencies. Based on the results of this review, the Company is implementing certain cost actions including a reduction in the Company’s current workforce, the closure of open and planned positions, and reductions in other non-headcount-related expenses across the business. These actions are expected to result in approximately $7 million in annual cash savings and enable the Company to achieve positive cash flow by the end of 2027 without additional financing.

The Company does not expect these actions to impact its 2024 revenue or gross margin outlook and plans to continue to invest in key initiatives that are expected to drive future revenue growth and gross margin improvement, including product development and cost reduction programs.

The Company expects to record a related charge of approximately $0.7 million in the third quarter of 2024.
2024 Outlook
The Company is reaffirming its full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023, and the placement of at least 20 systems. The Company continues to expect gross margin to be positive for the third and fourth quarters of 2024.
Webcast Details
The Company will host a conference call before the market opens today, August 2, 2024, at 8:30 a.m. ET to discuss its second quarter 2024 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance for full year 2024 revenue; the Company's operational efficiency program, including the expected costs, timing, savings and other intended benefits thereof; the Company's expectations for achieving positive cash flow by the end of 2027 without additional financing; the Company's financial position and cash runway; the Company's ability to drive substantial shareholder value; expected placements of Growth Direct systems, the anticipated timing of such placements and the impact on the Company’s revenue; and intentions regarding the Company’s commercial execution and improvements to gross margins.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar


expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the Company’s ability to implement and realize the intended benefits of its operational efficiency program; the Company's ability to achieve positive cash flow without requiring additional financing; the impact of the operational efficiency program on the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor Contact
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact
media@rapidmicrobio.com



RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Revenue:
Product revenue$4,537 $3,169 $8,250 $6,493 
Service revenue2,081 1,833 3,979 3,544 
Total revenue6,618 5,002 12,229 10,037 
Costs and operating expenses:
Cost of product revenue4,917 4,689 10,090 9,670 
Cost of service revenue1,890 2,205 3,851 4,049 
Research and development3,744 3,233 7,586 6,386 
Sales and marketing3,627 3,201 6,908 6,663 
General and administrative5,818 6,728 11,445 13,195 
Total costs and operating expenses19,996 20,056 39,880 39,963 
Loss from operations(13,378)(15,054)(27,651)(29,926)
Other income (expense):
Interest income, net838 1,073 1,821 2,076 
Other expense, net(23)(29)(52)(40)
Total other income, net815 1,044 1,769 2,036 
Loss before income taxes(12,563)(14,010)(25,882)(27,890)
Income tax expense15 6 18 13 
Net loss$(12,578)$(14,016)$(25,900)$(27,903)
Net loss per share — basic and diluted$(0.29)$(0.33)$(0.60)$(0.65)
Weighted average common shares outstanding — basic and diluted43,616,50143,059,93743,431,17042,936,941


RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
June 30,
2024		December 31,
2023
Assets
Current assets:
Cash and cash equivalents$37,121 $24,285 
Short-term investments32,269 67,768 
Accounts receivable5,011 5,532 
Inventory21,429 19,961 
Prepaid expenses and other current assets2,367 2,869 
Total current assets98,197 120,415 
Property and equipment, net12,273 12,832 
Right-of-use assets, net5,733 6,240 
Long-term investments— 2,911 
Other long-term assets598 770 
Restricted cash284 284 
Total assets$117,085 $143,452 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$2,180 $1,973 
Accrued expenses and other current liabilities7,819 9,907 
Deferred revenue5,427 5,974 
Lease liabilities, short-term1,173 1,132 
Total current liabilities16,599 18,986 
Lease liabilities, long-term5,616 6,214 
Other long-term liabilities281 263 
Total liabilities22,496 25,463 
Total stockholders’ equity94,589 117,989 
Total liabilities and stockholders’ equity$117,085 $143,452 

RAPID MICRO BIOSYSTEMS, INC.
Unaudited Cash, Cash Equivalents and Investments
(in thousands)

June 30,
2024		December 31,
2023
Cash and cash equivalents$37,121 $24,285 
Short-term investments32,269 67,768 
Long-term investments— 2,911 
Cash, cash equivalents and investments$69,390 $94,964 

 EX-101.SCH 3 rpid-20240802.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 rpid-20240802_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 rpid-20240802_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Security Exchange Name Security Exchange Name Entity Ex Transition Period Entity Ex Transition Period Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Cover [Abstract] Cover [Abstract] City Area Code City Area Code Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Address Type [Domain] Address Type [Domain] Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Former Address Former Address [Member] Document Period End Date Document Period End Date Document Type Document Type Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] EX-101.PRE 6 rpid-20240802_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover Page
Aug. 02, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Aug. 02, 2024
Entity Registrant Name RAPID MICRO BIOSYSTEMS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40592
Entity Tax Identification Number 20-8121647
Entity Address, Address Line One 25 Hartwell Avenue,
Entity Address, City or Town Lexington,
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02421
City Area Code 978
Local Phone Number 349-3200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.01 par value per share
Trading Symbol RPID
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001380106
Amendment Flag false
Former Address  
Document Information [Line Items]  
Entity Address, Address Line One 1001 Pawtucket Boulevard West
Entity Address, Address Line Two Suite 280
Entity Address, City or Town Lowell
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01854
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 2 24 1 false 1 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://rapidmicrobio.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports rpid-20240802.htm rpid-20240802.xsd rpid-20240802_def.xml rpid-20240802_lab.xml rpid-20240802_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rpid-20240802.htm": { "nsprefix": "rpid", "nsuri": "http://rapidmicrobio.com/20240802", "dts": { "inline": { "local": [ "rpid-20240802.htm" ] }, "schema": { "local": [ "rpid-20240802.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "definitionLink": { "local": [ "rpid-20240802_def.xml" ] }, "labelLink": { "local": [ "rpid-20240802_lab.xml" ] }, "presentationLink": { "local": [ "rpid-20240802_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 28 }, "report": { "R1": { "role": "http://rapidmicrobio.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rpid-20240802.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rpid-20240802.htm", "first": true, "unique": true } } }, "tag": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Former Address", "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r6", "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001380106-24-000162-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001380106-24-000162-xbrl.zip M4$L#!!0 ( $TX EE=&RUMYAT +2G 0 > '@Y.3%X,C R-# N:'1M[5U9<]LXMGZ_OP+727_._Q,?D0^]F812GQ$T93%I!,\&A(O@5,7)/C8WW563R9)GPX2HEK MNTWR+4ZN^0U5YU.>ANQM/LZ;7]6_W_PJ'_*F'P?3MV\"?D-X\-L1MYGGV0%E MW4ZSW6QVFMW L1V/T7;/<]G 'ORKXQ[!O7"]NDFDTY#]=C3FT?&(X01.FJU) M>GK+@W1TXMCV3T?RNK=O!G&4PM,2N%G]5&,4(VV\8O>I.6MG1I,A3"Z-)S = MF%G*OJ?'-.3#Z$02[$@].+_3F+SGL9B*E(T%N623.$D%N6)^' 7D[QE-4I8H>?N= M1S3R.0WA*I&%J=AE:1V8S80& 8CS<<@&Z8G77N3/OS.1\L%4'>)1 -)[D)?M1IO _$(>1Q:^Q/QX_&$ M)F"#TIBD([8\+EP%0WLU[XW@O=.R@7-_* 9^X GSTY]?.)WF*5$:328A]8&7 MMQS.TXBP[UQ(G@-_B-,BPS#N@T)/1C094^(#/^(Q,+GFKA'<_9TG(EWD+E&& M^PI4D8<\G>[$9WL#GVLV&\%F8+ 01-&<\/$DB6^ E?TI\5IDPA(?*$J'C$QB M'H%KWLT^6R %<@SP G>/,9""MCA$LY8.(Z3C713%6>0S06)@)$W!?X,FL\& M^YQ%_I2 O P3.@9&TI1P ;H_ 4.AF,LBV@^9Y/$9\CR:XE'JCS@@ Y &P5,. M/WPJ1F00QK?2@,192G J^E$#A?NB82T01@C$):/ _ 30^B +0S)E5*.]-(:A M"\PWS'@ ?)/@#P0C9!14_*7;:=AWPL#B<@@5%FS%P@-WPH#+X9AF_]'62'!U MF.:V41[.(GLI9FJNC9D^@E>-ABD2[M,[B[S+AC -@%MM^]2U% M>_?'QR_MS M\OG\V]6WB\OSUQ"?'A-7J&V2DFT M3[72RG\YIZ_1JA,.!N&&2KT-^0 <@+0#8!]2YH\BH,%PJI@62=MPPU&&@.=" M ,^)GX!>^R G- ,,(,T)$7&8X0\A>4Q]1!8T568C-S0I.*@H@Y-IEN!XZ%X& M(",6$10FD3"4&"EL(T;#=.2#S.#C@\Q/8;%I'- IW*1L64 X>*%!$5 F*J D M@SA9Y],8F(F _"V+F**V9RMR-W8"JMM%\*F$Y^<77O/TZRB)L^%HSN>.:#C( M':Y%;AD< +[V&4,,Q_Q,:N8M [5#@M/@1IEB$F<)S!S< 1MR'^C,8^0K.@E0 M7]\';J"K@ OOB@TP703\&3,:P>6HX%.-0;1-**")D%, R0+DB%SC_UD9?QF= M6EIP04;@\&7<9TE*KB; !2:X1?X$OG/T '+DL_,OC5SNOX[ D8WC!.13*>W%(($H?3DIE @8@ MI"#EC%80YS2]AJO(U6RT9@AG@5YP"=F15%$^6_\LQVNTU+/C_(@&8X)8!%GL)4NON137P4DQZ%( $@Q!\ZG+:0,(. M&0\TR!\L@N?F,&7,(RZ='UJ&8AX!6U&BW;(9J","'N./Y/@!R$(83\8Y+B%S6WU>C^)*^$QWL_800D$"3 -,.IM9T@N\[U1X=%\R4X!5SB MZ 3PMR3V2E$NOZL?IV">3^S9+;0OY/':,Y"\[NL>/',"3I\<0F!0 M??*R,Y<64?!DAI5&-" 1(&W6!U>4I0BT94Q-9;BU5URZI\X_&>BV.T"^+W-Q MU?DLKOI3Q54;)K?=6#VG2,@U743 (&"P3 (8N$Y4S&7*G(ZIP"_ 5.B@[R-DVNP M#1AERE 5S$:6,+4R%DE9!V0>8;"9NP:A5*!XA(3F,=R=@!J@':>EU MX,;"V5)?)@SP07F@"^2 N$.P8A5HK.9#?,2R2LY;0YAAAG 0=5M03$XH MO=X[L <4(/-:<*\R<)WML?YCJ;(Q&C$?!08Q,"V*4\T0I,P!(09KL:!I/U%3EXS$'=4)PE8A$K7+ N%RFH, MLA1EM4AIJQ@5GS%<4S-3"9*9DNCLXPIZZ/?I[V=YH1LHK_K79/0"L%V0#",JC4%"A"LB MU4\6J8[EONL&-Y]EBB.+!"X"MH4X!5OCF"+ VG7V$QEKX*7+$P<5SW.!BT^" M&<>)1;(HC/UKV8:'KC&^58 )UCDO*VC6&!HHY=M0!%B2VR\+_"%N"4C0:F4) M]666,L]HKB^$6F"/4KQ%4H5+UZ\*BS2E<'?*A@DN(V'#+*1S =]?&?>O&=8N M?2Y%>TSU[#'YJ^L["#X &JJ)@QE'@"X%5D'KHM ILLD$KQL@/(<(&D1BG2 O M @+01XPNM4V'%<[W7% A(*X#.4AU3F<$\O^/QE5CB?H@)!]CK)DOW6,I*NA> M2&#-K.YT!6?^PQ((7$!@_V!8EIW.0,UGABJ$)V&ZOX,9'Z,_XY&LWZ82/TV4 MLMX W2#DOKU=XRW@OD$L"[?SP2K0\?_)*QP)GC EUU%\&Z%>?X49 0E>HP_Z M^46[>;HP()&^A'SDT34++J(2N1,@WRU-@N./ +^165=H%V5:SL0U; (^(*>( MET5AI574R6026*XOU.L3Q?JD]&D#IMLM4#NNF I#W"C3[1SO?(FD MG9Z'(!O$?BR;891L%K< L@)6EY41N)&,59&" ZDG8AD!J]F4!SL3N8 M, =^*"0C[G*"5CS#Y7QJ M0?KQ/%V!^01L<>)C.?/Y[)1*FJ')E2U,?7#' \2N>)C%@W634,-JTX3S5[DL MF=!X<#9KW0-GF#G/_RE3CL](LNB63M?=1?NJ_WRW#A0U0D&QN58 F/4ZMRNL M D?X?"*3%(J^>(/$/BOM!"Q/5FT ]0N,5R4!=%22SMO%:=;SE#=E:1K-)9XD MTEMHES+2**\W:!>(6,=2KA E3N,,?@(NQMXLF,TVHX8"R# 1H6!R#DLUI--I MP:(/3!^F?+QRJ.#TRADALO'*4=U^M7P8;1@#U+-FG#S9L'H/CJ,:;A\3-F!Y:-C.ET^%/?_K8K2RR23&PBO'\/;\V,PD"E!F0/&;TS1UE=LL$P%2 MCF! Q;1YQEZ+GCR(!25T=7 D8%.W:/-U19:'TD3T $P,CJ5%X'EE3Y- 1B$ M&0Q[VQ'@2DE164=5Y)D9&@ R(;JYX4BB!,SL;#%2&MGH!T!,J8'\INMY=!.' M,">-QF'R6:1^)UQ<"XSL=(%.(BV9\D$K-5&DN!UQ'[LV(5*DF:JG9'-=SC*/ M-1C VM"<)+K!)I$)I6EQE28X1GF)K URU<*"UVQA=HN@,Z[-" FV E7R5(M@*:W/DK''Q'B_ B1%@_)UQ6R>02X?.%XB,U\8 ,Q:J19;K'0*2U%#T48)@KH$*(S9 MU35T*IX7,5WC4W4YV7Y:Y+54_QB=I#*SDN??9$RAPIDM \^1$IPUF PN1KHM MC"L#((E;H%RX PL4>;'P!B,46;?0J:U@2])*)ZAVX^O\XY!?$UD!3 M):P6>O(U\1?H)U3SJJ:4-%E%J4_FJSC8#C"J:+QV6D#"Y/2Q8!#,!$ BZ23!O;9? _P,2, M2FNM,PYC3/UAY2 &WA(P\W#EC 'Y8#IN*Q)7R+ 8@US LS)"SJ) Y^M\*B>2 MXYU+F#CY75V>PYX-'1JZN1U6I5Z[@%8)G-*8./;QW\'$%1L"E@)[G&01W,.@ M>2(ZSZ->G1=Y5!GO2TR>KP"]$@3DV220E)5N!W"M#.7E_[68*@K )&0L.YO& M^9FE_1L"@%FA0UM4./_+0OT$D!%+%M,P+6F&!6A1QT"YT L MV%R'@JXVS2 Z +;I-*'L7LU[+J0,I?2:29\^?QGP0C&(R/+1#1=L MN]\'M@9L4]HFSE>=6U#MG) XZB&#-?=90#AT7BA!6FB4*U8P)*2W.P>X3YQB M+,3K#&&?GSY95]UZY/P)E(6RD+QG- /9S"QR]ON[9Y[3_^'>AF+[E;5.(^66 MK#@!PX0B@F8FB[A.F3_S[ NKL)H81\M@J%A^@EB)&B*38YS+CM0K3T_Z[F^1 M:AZ9'.'[LAOUB<7S\MV?%Q_(IXNSRR_D_<67JW]>?3W_= 6FX?/93CV0SS+I M?T04@EUTYZ!7 ?:@RE\@1%SAFUEY";U"\N=CTW"MZ)9UXG DJLR3:!ZL6 M?]E<633\TS'VX(K7>R]E4ZNY[ 68Z68"Z.08EAO2B6 G^8]3P-[8SG+"(SEY M>=.I%F:MT*@8-P!M,&K3$Y!S4:=G.M.PE=ZD,)TTR)^L3S?DJ5_38/5>V#>NX#;N[^=9MPVX_U[3;]63KR3:=S0]=NA.T34 ,\=N1=Y1? ME^M=%$>LOA+_)(7E6'.+?G?*B4TX;?H37#<2Y+QX,0;Q;*LPZ9L)656J7/'O M/XXFY9/MV:7:C4N4B3@"@1%!=IR6BK\+[R-[R&H/BF3>XTI_=0A3R])SRY)Y M>,)HB]^G_O4P@7@O.-8L]WW&!H-M8H1OC7L:(=IA-YK,,!0-6-W3711PTYH? M1S/OHNA#QJAG6*$9FFR4$N/7+90M8\RVGW:IFK9>X) MU]:UW)9=RUPMZKT%F;_*)7>-:"O)I,X1!FX>,#]P(P>O6[53)+HNMMJ^UT[Q>M[%S1-2*..33& MMBS;=FO&5H^QCFNY[CT3J35GC>:L;=GW+&K,/GBDA:FE:/:?\O2259U*[ M6_[FBXHS"?%_K_SM"A7G4L]J=RK$))/!1,F@3(GK^SF4$0==YW>L[M[VU^#" M5S69Y%JNW:J99#:3/*O;JCMF#&=2T[*;%6K&,!E+E S)E#@IL^GSV >6E?&L MSMX]/ 9'*55EDKMWRV+-I"=F4L=J==LUD\QF4MORJL0DD\%$R:!,B9,R5\6; MYHLWT!]80L:SVNZ^M26#(Y2J,LFUZUC?<":UK9Z];Y]OS:0G9U*[7:$M3";C MB)*AF!(G9/Y@$4MHJ#]G,^81%VDBWX9^8"F9EM6][U8+$V.4:C*I;77CVKV[UG$US-6<,YV[MO>JE,JRW M8\V:J]7BJMNQVBVGYFK%N HXS&U7G*LF@Z"20; 2ON'C2SIB">&1'X\9>:7S M8J_K=WO4,RS3#,VS'26S7"7N6KC #\\QD6HC9I&('=H6DJY7%\(-9Y%CV9UZ M XGQ3.JZ^_;'UDQZZH(6:%*]@>0 KCRD#20J#-/AU_TA3'D;JE^YWNYY%H,[ MJ:O*G5[-'7.YTW)K[IC+G:9=">Z8#!5*!E2VP-&2-%7&>:)R,=9D:%0R8%;B M#)+LI>RS09RPO)R?TN_U%I>YSCO7:K7WSS*980SJ5OE-7&U:MK-_A%USU6BN MNBVKV]T_JU5SU6RN=O"UW17GJLF J&1PK,QYLHL"@^5EO0-K2KIO'LS$$*N: M'*I0%T4U&52_A,AX#E6HI\]DZ% RX%+"C2"?64K"6*SDBWY@A&(<#5[^H,6; M;<-D8FR?C<9E"LMJ\:V^^&(&<(]=FK7XUN)KSJHQU=FS*YH4J\6W^N+; ?&M M>E7-Y."D9*'1^@#8:,W.0R,R80D1(YHP\O.+KNNXIZ1/!??5!\QXF*4L>$"K MB0?"'L19/V35-X%[KMYP&V@W]MD?L=_:GSD[5,OO0H[E=.R:HH]$41?DLVWUFD^E]>8Y20-<]*\I!?&!_P?\YNT;^)/?H7G5 M; $S)['@^![SDX2%\M-YI[<\2$>:D?-W*8DZL6>WT+Z(T=.MW**D[NV;/LY" M"X \//\7A^;!;T?<9IYG!Y1U.\UVL]EI=@/'=CQ&VSW/90-[\*_.47[/*,EG M,P&G?-Q/&+T^IH.4)2[YSSG1Z+)$ :3Z7][4?U\AB_T MVUW3SN"V?L)WU;#.LH:Y./O+=W]>?""?+LXNOY#W%U^N_GGU]?S3E44N/I\U M%IPD_W&:*S2/Y*/E3:=Z,*V$*,Q+ M!E\219V>R7G#5K*NT;I^LC[=D*>6PC=UKMUKN+:W\;3=<#:>VS:LXS:Z7N]> MPVX_U[3;CS_99L-NN3L->T=$M(+:%]M.U MW>8.SKZJI/C ?#;NLX0 D-3D\!;(4:V@>3T1W@DQ;[8?!H W5-E+]@KI0R@W MGV5) @I)J&3__5_%OG]F[NG'.*CO49Y1,9()+1]_L+\R?D-#X/3>/==5SNRO M6Z+9T;G7L9R]7QMLWHO>:J$KD]"Y3+]-_N5]N6W+LIWR0Y_*,ZGEN354>!):7P ^B-(XF1X8.G =J^G6Z,!P M+CGX8?%G_,+-0:&#/Q,VH3S(7_\C9.I'O3C;7TCQ'1AF<"VOW:DQ@^E,ZNX= M[)F*&7J&&PKU2OU'L FKG<'E?VE@KVLYO7W-Q5Z$*!'DJ!1G'=>VFF9^+:%: MU>5-\"2>P'2F$I9@,6J"6# MXTPP#40.\7O*+:OC5>C%?M5D4MMRFW;I4QE&FX./<31\G+)G>=V.WHY6HP.S MV>1:O>\N::\+_]TG(YE[]V%7*;B M3"W#E9=A?%U%:]^\J0]CA\Y[?.0IUSWQUREL7\]BD,@JY"IE\XI.?\K MX^GFAKK'>1&(01LA=YKB(60<\IV0X4Q(ZNV0E>F/*[KG)W2ZKG6^WI!6)C_J M6DYWW[R+>8%Q+7-EDCG'ZCUGW\9!;6P :YUD;&LW\YR;/K"J0,?J.O7F!\.9 MU+-Z]CT;20V*YLIA+3ZP 0.C$)"$W; H.[QMD4VWWN)@/)-ZG:K4"4RW!Q\9 M%6P>(%A$%"]5.#"P@*_&K;L+S6?2WLW&AH(%MV6X<5C<__30*.+AGQ8T4!K; M5JMWS^UX9M39'A%J5(NS7:O7;9O(V3M,D*$OZ:YX160-CBH:,@\,1K7P2Q@U MC#*;26W+=?:-LUFKU[(@N%CSUAG3%K+CQRLW37.#?&ZYZVD_>MGK-;R>=Y]O7G;GY%T&MU6YP=\\[+C-'_,9'?[0&?]S;Z&MZX^U^YZ8 <\N/>HE-K*I,8L%3'L.H+*0IOV&ZF*+6/W^77H@]NX7V8=I9 MNGK+QGK1PM]^'$SA?Z-T'+[]+U!+ P04 " !-. )9SIMR1@H: #ZD@ M$0 ')P:60M,C R-# X,#(N:'1M[5U9=]LXLG[O7X&KGIDXYU@+M=B2G'B. MHS@]GDX^W .1D(4.1; !TI+FUT]5 5RT6);=\1)W7A*+"U HU(X/ MX)N_SR8ANQ;:2!6]?>75&J^8B'P5R.CJ[:NCB\')R:N_'_[PYG^JU7^_.__( MWBL_G8@H80,M>"("-I7)F"5CP7Y5^HN\YNPLY,E(Z4FU:E\;J'BNY=4X8:/::+>ZU7:GW:KV6HU>U>L%K49K;Z_M=;J[5WU?=+S. MG@BJ0;"_7VV/]D;5H1>TJJUVT_.[C6;0Z_1V@S[?:XM1BW=&7D.T@TZKZ_M< M>'Z[._3VO+W1D/H=)S!F&'=D^G*6O*V,DR3NU^O3Z;0V&^JPIO1574:AC 2. MN9YH'AD<$D^ 2748!A#;K'K-BFUDH8%IBU[W>KU>?88=N8?Z,R/7/=AL-+SZ MOS]]O/#'8L*K,C()CWR1OP54?+FY [R;/1J(H@,:AA%^[4I=U^$&$MVN%&.N MPKV%5K-G-PW;ZU0;W6K+*]I9SSIXLE5J*'M\922E%QJM.MX>^IO'Y;&:@H M 3&O7LYC>,VWO]Y6$C%+ZC2K]<,??OCA32*34!SJ6 95Y' #!/%-W5Y\4[=- M#U4P/WP3R&MFDGDHWE8":>*0S_N1B@00(&=]?%!H^Z<, A'1GW#_%'1-2]_V M/TO.Q>AMQ:_"!$1\@BT)V3^.H+OY *C3/#R) C'[6U20_0)AU!&(ZY0JNS/ #J;Q:'T9?))3(;012#A+CFFDJ@?!0',H1'&_8$:>C23 MIG*(SWP T13:W;+-O*FO;3UG1$[$\YN:^J+ UDNVH@X6Q9H5G#%YF]_[?Q3L MXAUGBB8RJHX%.N=^NQ,G!U,9)..^UVC\M4+/';XQ,0=='6I4)ONW;62E*22X MRD-Y%8&K!O(UM)#P82BR!X9* ^%57X4ACXWH9W\<9/;0>HPJO70PX?H*B!NJ M)%&3/M(&,4HB?1ZZ3J@_>]N1W>O5NNTN4IX ?Y(@Z]@-J@:#JJ]>[W5KO<;Z M6XV:1]?KU)[.;CJ&M>*D0N_ 0) S;RNMRM)8'?7P) M4BKSX$;3B(.8!AE?] M!O.@C:R#.@U\2\YBA]E]Z%_I/K:,C8] =L <3V0X[[^Z! 4R[%1,V;F:\.C5 MK@&7#KY?RY%]T,C_B+[7!/;2SZD=VCZT0W/AANHU42!^.3VY/'[/+BZ/+H\O M%J7A&5)[<3SXY?SD\N3X@AV=OF?'_Q[\X^CTIV,V^/SIT\G%QW>B^KL"$O6@9LRH4 ;?M/Y]^'S^B6T?LV69 MFHU@;60&3J!;_7DU+/LN4B],I+:S,& ASX]/+]GY\=GG\\OG;@_/4FU2'B4L M4>Q"^)B4,J_%E&9>9R=X?2/YJV+W3 :D1E0X@;&D6B82VCV>^6-(@@0[\A,& MM[U>J_WNJB/)TM')XE%ZE0$ESEVI0WY;]V^OMO3C[YSB1 MJ+C?? Q]W-+#WK7J#\\_LWCY0P:)[QG4&+(PE(M;J&MLI_'(;8@<1\BG7:PK%SGHDP9^2P1]D*.#A(5A' MQZP.%E2]:KO1Z36_ M(;W$[$A!DJ'9;Y!CF$!2VD3U7/#ELJS']*B^XI'\#_U^_=+$:F>@)A-I3,8 M5#)F1>7EC?6D=EZ[J+'C21RJN= TX$4E8:>J]OHKB7\H1BLA0C[\YQ?2_NU' M;Z]Q<%13[ MTH7KGLP_4Q FA?\G8QM#N7IM ]Q^L]WTMF#_GT9[=QS',!N--4BJC'G(Q$SX M:2*O,4D%$R?,ZT<4T6?H $"2&(K2&A/_W,O2VVL06L8C+?B"SGB5P]Y^=UEC MJMNW^E'!')Z-5;04@WO-RF&KW:NVFHW&-U?%*6I5?_NQV_3V#PQ+1"AB'":+ M:)R[&!"&*0HY@Z2, X_*\K/MR-;!!1Z3(=T_+F3-.WE_KU4Y]" [8V=\FJ3^ M%Y&P=RH-Q377 ?M5F&196'8W>^BM>F_FO4,>?9%*B/6;W16QO'=/JS&'!RGH M1X7QS5?KY(: P]M;%W'5[4?8I%WI_2PTD7_.'%IOV^I7>L?"_T&HCCV.M M(&S"XL!0S=A0A&J*8H,W49I8M_HS&\D0O8 TX!(2$04@3HEB1D[2,.&14*D) MY\Q 'FE&P.B@Q,S?]+==Q MER*P@KO?1-G;J_5:F^5V:Q7HU+K[6ZG 5\H,$A5O+\._0L/8N+FO]#;N%A#^ MJF4"\HJ5GC1RA0YS*V#9@WQ:?=VJZL:#H;UCWK5H&K[>3\??3M;=L_&):K5KO;W-1+TD",,E M[J.U4&)_S/R0&W,'*_B25G,N-4=BJ;!^,9\,83A_4DZ<.A@JB83(/ "8P^E8 M^F-B4&$W[X)N<-;1P2?7E?R>&7_6^X\[I);6T\R]YI 4+8\^FI7# >H:.V(8 MQP!O+Q+E?]EE?P'S[K&8:W;-PU2P&'K[!D/0DRC .%RPX9SYM&X L> 7,+""@(1+17UI&% (03R& MBU?L2JMI,L9P/L9"/S".&7$_T2T#RSIZ]+@1*>%'^H@4*_9:1_<9XWV:35HM$$G$&6Q5L'DRH+9 M&-2'C NH3Z0H^TN-H*=@I&Y9#D_ID901VE,DD*W45SC'SNE\)I24"(8&=[2X ME@;> Z7DD8^54^[[B-['A_&8G(#KP-@%N>"FU+.UP_/4LZQMM6]$'F>7.=?L MUL+;:S)[FVHR6POB]MB8;VQ!\]XK\>T'/T9CN_-1]M>>CU*R_(W<]-\RB>4# M56)EI:RO1<@1G;ARQ$HQ5AIDHWB%#R$22Y/55VX[E<7^.]9%&'@EJD,M^)- @;'&&S>'!ZM*:^-D,/,0(_=;>]L*SO8-/1PKUQO8SQ%; MW$*]R\YY#%G")^EKQ=Y)9>:0 .,-FX\"Y>_KE';R&@-&D MX%"&?4"$S$*3#[+#?4]IR MRJP__&<:"=9J6#)KD,/Z*LX!)XM=8NB:)!Q<<("!ZO%L+(/9=MC<0.&%LG\+M*T MG? LFOJ]M>B81Q0G:K$O$^C?WRQ@N/N3LBH9Y8<-LE&J(VEP8K)Z/S Y5^@R M4-7-&J,)RZ<3IR!1NUB>"$.*G88",A$(R8),+D(3*X-E\2\_G.G ;KXM:PJQ&#/I\#?,($GG9A:%H-RA9'M."_"T+'D9_#I]U([3#Y5ZKPZ@L/EBQQ"\'?KM8BQ,Q[0DO M!B9FI' (%4N(,B#&I/[847-KQG4O8;Y)3[8, SKE.&!CBX_NU;Q.YM5:M89W MDU<[51#@48WTO0@ADR!8GF8?N Q3+2B,=[@]CMX-[J,Y_NB>I,0:'K]PF< ! MHU 9I E;=$]ME2H_N0G:Z-&.,,6!5,@B&2%X]D/0_6"7C+L8:O I\\+9H;@[ M/P:JY0L(Y-"#@5TIMM.%(D$O--)J0L^[(E'&V'^EP(=1OL )_!V-&/*T5%"B M.JLK)+&/'P=8M" C8N_G+I3ZI>RN3!@9"KPP!,<<:Q2"S%-F]5S?UG.-K><6 ME5Q7V3K]T>L2^UOPHE;IU;B8%\_.RVOROCAL:[9< M@+ X75.X@_9?1C8IEG@0;'%J,42] *LMJO2-I7.=(2 MXG5U0&=IEX2 M*O3[C0@?]YIOE[@\SN@X(PH."\HR!A>8Y<**P-\81AVI#@- MV'@Q!.>R' M>F85Y9Q.,X\!U@+1@')2XJ8.ACD%!4(3A3YYS!ALCX. -,X9$ MT/2XL6+1 GM'G0(GC.P"FV/K%70#6RNWD-4ML+H1DQ.>@1O;TF+*S!/>H)V ECZRGV*?V.PL:?6'SDT'QOBTV%4I] MA%;+SU),))U(RGAY4P.+7+5Q,TRMXQ3Y 9DXY+ZYE[0$VQ!AI73"YRX,*\>*C$(W2T!FU4BAV7YW) J];'<5B-+;H*%;#A*^1)>*^_-7 M U>-JQ!::.XG?9-.(!"9'SRC6FAO0]985#QI4R8JDBV%NOK*=O'6/I:\;5F^ MBI#3OM?-(C 7;E7QRA/%6Z5#0A^_^T6^[-5:M/!Q)^XZ^?DFUH.\9JW1O2M. M\J'QDUT\;*[U0/C)++EX>-C1[?+FM?^:RQ:>\_,H8,%GQX#W C)0&=.)5_=# M C9J^YT%1-0MH*B;]RILJA>.1@_&!$M< /&57=[J4UD"GP*:^%K'):S8'#PY M@6SYPRY[K<9,S&:]GC>CW[5Q,JD<8N'_39U_]1.)7HX8=)Z[&&PD<$LQ.*.E MO7.WM =AXL8%RH"6(Y:/A5XK1 ^Q<^F[-;BO-?AQJR_=>(V;9O,Q#RG[KO)_ M3.6WF^N! K:S,WXE0+4A9^6V*OB>)YS1$8\[=EDYL:O\-AYF^&&ZUYLT_NXP MW3^84K9N R#==.#%8Z_@W_ M"9Y2 57/BPP2S/$5UU0K_:#T%/ZL?E3J"_XN MLLS-2(B7 :)Q&(?-4!)71"5\"_$J=+PR14:.I2]IRQT3P;-Z=X96:.X?;896 MEY?W=RF]SU_UCN^!=*BQHS LTXAG!"LB- A!>$ZE]12 M22JOR5VE,J"B%2Z-C5(8,WYCPG[0% NA>-HGLQ$&@ZS;+]5/KK2"N,3JL3E8 MJB^J#':&!QB.\M)HK-65YI,RS,5B?F.+!?:5P=$E,!0PB%>8_'.C-D(UWB']JP?7,B# MV8'1[Y- *F!M:0'% ;:BJX.UO+3@ECF53S6V;](AXHYIU8C6CFVYV2Y-+Q-< MH,&^XR]OQ%\^IIO8:/(R7I)HDASI-(*Q'Q2R7%(7D"F[0X"]EQHK['G,3@=7 M@83@49^DO"3Y>9E]2>7<*A1:#%<:7I9!I[,'%KY'WW8E#=AL!6C#NB;A- MNI%!9QJB$$L!R/6"SG]]J-_S='$$3H(>U81,AH!IFZN42O_NPY_S39X-;0LM M. "I5W.WRF"RI50P,?C.;H;7YG*Q@DD< MKFDG6Y=8O0[.:?EBL/J<@"F;K&G7JL3RU2O%P^5KUKPO7YWP^?(E12M5?=O5HNV95R"\$2:&#Q6#0@7C-#;+OHB;7P53IP-3R MB'G-\S*Z5B'0]"524VN!TLC^K:7Y L2G$*MH;)*B.%KD0^&/+2N*=7L+_ !# MF9;@U>B8)1Y4DA^N%,[M@K!=3;1/.88CHD33FK^TR%,"F]Y$^JT1V2T!0XXM M<"O#8 3_XU '*Q&/6RG<'&(MAQ>EOFPD)-;%05G08R$P=%SNC>%/YHA&&4C% M?6UAE1:SY*W6DX-C*O MF7ZO1)8&O ,M/0.O0H6?2X9+%@^,.%V@X-;H;")$ M0MW%Z1!RP'">8?2!RWE 7&CB0BC)A\B?!5KIR7R;Q?K>,U' MK3,\,L36LDE M-D,;AH>B\/,Y#"AR)X(3:($> ;;Z]*'H]7U%PB*I N!JJ&+:'P>O!*GO# (/ M>&Q!V<(?DUI3)F(SHAL:+;$/S#Q8!6G&U-@$E9&[70!%6(1+Y:&@7=\9+(& MMI!,JPF%.A,L8 XQYO@=$:3)G*R%5B&014OBM\]CN6MP\2GF4A9\ 7_18QO4 MP,4V],!"7),Q>X%G$#=(XE+XH1#1XN*[$*&9:.3P\%.!,%279JYYW:1Q'.+.3"0@ MD$:G<;$S:%&E930*>:%,Q8T)AUE#5(N"^6-@K>$IR^BL$9>H33 K1B7%25&8 M]D*D0PET =7W.1&0><)S()A]L(]G#E&NCW/_9;?&P&B6TF^O4?T7HQT0!9JF ME/?;A7^7^Q>?31%(+LG>+/KAFD-Q%95'96Q(#.5SO,0OLA]'/261LK;29PX MY>!7B#%"/KTYJWHFZ?\=*K][E6=0,UC"F3S"-SFW0RY=G/QT>G3YR_F&3\YO M(/W)RA\K7RQ>@DR;K:NM:\X$"!# 3;%[8#7)?7L7ND$L'@S< KTI_A)C'HZR MTAT9!/< 5@33"",@; XBCK'2,+C@Q6&1[G' W(W'PM5ZO:]S;G>G#41MAC5M MN?*\=M%R[WF="KDE8F?S=W-7(3Q+-M^[]\FEJ^QZH)-+GY2]^/7L_@KJ86MH MV+3,^_-QIG1Z=FV MJ=$]"$DYFSN!ZSL(6,X+RJJYV'JR6ZX'G7 %/H7 !1 M4* -56NDUH"^P7BNRDR1)\I#X MV(^C!,?3.,)IY*9K-Q-Y'+1>6%OA]XMY^7WRS4 MV6-KRNX&Z.U*U#T^\HQZ123T<-'2XC=<$'UK:"[XBG(WYXUG\O5U: XB2@FZ MZA1\U(6Y@))TM9H['?O9D9J6% I=]1I,70> ([4BH@+UA30@6Y+#6[PN)@B9 M:M"FY4(A]H1[5(X@35-O:_)ST*YZ2YX399OBQ7)8/#9''(0X"MRM+!SO36Z' MABB3BK F5[6I='AB]V=[PX2D6OOT%"!^^F1A9)C+44^\QX9&I3D+QE2WL^7&' M[\E[R"O$G-1Y5X_G#5OJ6=I>V)=ROVB\X:;9W8^VD17L5MQB\@M02P,$% M @ 33@"620PK7M4" &CX !4 !R<&ED+3(P,C0P.# R7V1E9BYX;6S= MFUMSV[H1Q]_S*53WM;! W.%))B>>Q&?.F;YH<%G(G%"DAZ1C^]MW M24OQ14S2F$P[Y8LM4Q#VO_M; 8LE_?R7ZTVQ^ QUDU?EBX/LD!XLH Q5S,OU MBX/?S]X0<_#+RV?/GO^%D#___N'MXMD/(R_YCQ]7%39VOS]L%HTSLANW>K8^T,28P1PD5W! A!2>6 M4TLR&SGE2HE,FK^MCP+(3"J()$:MB4@J$9]%3KA@63"412MM/VF1EY^.NA_> M-;! ]\JF__/%P7G;7APMEU=75X?7OBX.JWJ]9)3RY6[TP7;X]=[X*]Z/SJRU MR_[=+T.;?&@@3ILM_WSW]F,XAXTC>=FTK@QW!M!\;+]\\+X:N;Q]$X+]N2?56VU0&T_$=G QD,]I=0'\][3N1/Y6&'M+O*XR5&5SZO#4&V6O;[C"I?B4[>& M[VNK<0+2K:@4%[]>Q-V'[PE TGF9=XO'6_QS.T-GZXE2X+J%,L+MBK$S4E3A MP:"B6Z^J+P$NG(>BO[J*D*]V6\A)V6T3;JL-3EK8-"M&I50\>&*%SXA07A/G M0R#619DRG83.Y#ZD9@>]@7"XKCXOTG3E?P,HS M" +0!45E)()R27Q,G$2M7#+!V8ET3J9<) M?$:QP!F5&=^V/V%^?&.G_6Z^/ %M]5-"/)0Q(^#?D_)KOSW\1V)6C[;])W'? M,STAZJ\6* ]!3\FEFCJH/YVT9\:[+&BBP#*"YQI)G$Z42.6XU. "U^'_@?"# MDNY_!/A'8CDQV#>X1D&]E?2N+^Y6EC+( "QAW.)"E?"XZA5+!)0#X;2P7(_; MS@>,3@EWJ )^2'8D@FJZ^.WCI%.4:)UG*Z>"U\PGW'!0C$@>ZQ)#/9$Q**HP M12//)BG+.FO_78 _M2C[X>#])(BG4.=5?%W&7UV+Y8,+*C(M24R@L7Q UTS& M*.$\.>882 V"$]>GAG'C-O=U7/L Z;]K:E>UO;@,K$3,;G7VQ8 M]UFKG\&:K90.NKL/2WA*W4WBE';BW,@%K-F/6/Q;6?=9Z M,M;'^/)]?59=E2LJA9 @<&,1MI,D44T2AH"0S)MD?# 3DKXS/#?.3PSI/F4S M&>6^/GQ?G];5Y[P,L*(V9E@W2&(S%HG07A+#,0^C#H$GP#HC&]?J^I;UN?$> M$]Q]Z'8RZ*=5T[KB7_E%?R((8'&!29PPR]'5E'";,=P3184!P%-BDFXZY ]L MSPWXTP,[T%$9U3+KEII7-;A>2/0J*",#8LZK:'+,L ZKK\EUCT15[]/ M"=>32).W-%'BHN-$>!U0D6$D2 HI&@_6CFMZ?-WV##A/%-@!WJ-Z7(]DG33- M)=3WQ5DC,F9X($HK%*< %YF$QW:E!#=6 6"U/R7U/07S8S\NR ,9,*KS]1'" M)6XO-QGS9WE;P*KKQ:3$$F%9=XR5$]$Y;.Z[X>FQQ!H1'!7& MZ*C^UEGMNG]R^7BS\56QHEPKR:@A24=/!%4&=Q- #R&ZF#QDB8TKNAZ8FP'+ MIX=O .2H%M8NJUY?AW-7KJ&_QQU82MXS3C*.6X906-M;$S6)*:*?2L3(QST/ M,F1U!EA'!W. [@2]JM<;J->8;O^HJZOV'+>)"U?>K#2N$99S3R*U$D_C@7>/ MI5D2918E&,,RH2=H5@T:GP'KJ4([\(S(J';55MH4^QL[/ M-X5;KSP>X:CI7*( M*//3RV?;R]V/[O^#7S[[-U!+ P04 " !-. )9=23^/X@, G;@ %0 M ')P:60M,C R-# X,#)?;&%B+GAM;,6=76_;.!:&[_LKM-F;76!8BQ^2J&+: M03?3+H+MM$6;P0RV6!C\3(2QI4!6FN3?+RG9J15+MDC9RDV;.LQY^9[X\3DZ MIM6??[E?+H+OJEQE1?[Z#+X,SP*5BT)F^=7KL]\OWP-Z]LN;%R]^_AL ?_[K MRX?@UT+<+E5>!>>E8I62P5U670?5M0K^*,J_LN\L^+Q@E2[*)0!OZA\[+VX> MRNSJN@I0B,AFV>:[Y:N$4BH0"T%(, 4D(ABD.$P!3"4.<1P3&-&?KEX)%<$H M5A)(F22 Z%@##B4&F" H:(AD&J5UT$66__7*_L'92@7&7KZJ__GZ[+JJ;E[- M9G=W=R_O>;EX6917,Q2&>+99?;9>?K^S_@[7JV&:IK/ZNX]+5UG70A,6SO[\ M[<-7<:V6#&3YJF*YL *K[-6J?O!#(5A59_W@OH+>%?9?8+,,V(< 1 ##E_?;F11 TZ2B+A?JB=&#__OW+1:]D.K,K9KFZLK_;SZK,"OFU8F7U@7&U,+NO MHU4/-^KUV2I;WBS4YK'K4NGNL(NR;$6UNTSM+F%L=_GW/K'9B.T?:;_5[EZ/ ML+G:[L=C[7%?3C\>;;N7YA5"G7[#6S*CM]P\H=[EEH4 M%5M,\+3X(;.UY85]X(/Y:BUC ^UY,:UUUB_=6UM5]Y7*I6I>+5NA@TR^/C-? MS:7*YN_R*JL>+DQI+&^*LG[A-J]5E3HO;O.J?#@OI)HSC2**D 8I4I&I9*$" M-$6F1"D1+S>?7X%)^K'/S^=;.;6M))[\S!=]7#;ZE6Q6TIFLIG]F"K M?K.M-\T.@M86?@KJ301%&:PW$MB=_#S[86%\&A=3)V5X*T5);V%:@*)^Z M+82KVQ^DK8S=VNI*B9=7Q?>9B32S#9C] M@O:L"&QI_M_%K?EAL/K!0'LKQ> M,1.%Z8%N*M!*N"Z+I9?9JO!Z1C0I-ULZ,[\NJ4K3]7;8:SUKORIQ6YKX[^[% MM7DJJ(]LJ>9()BD-(PU$Q!$@2'# *2> Q5QR*+#I7\50VKL$3HSW1C+8: 96 M=#C)G3DYC.Y8IVZL.IITPG*?$R\..P-.!MX^.]ND[5WGCE8#[KO[RY+EJ\QR MVS13M=')L4];Z0OA62O.K79V;+S^5 ME\5=/D\U2ZA4*1!"& 93'8%48M.=LU1R3$4B4NK&X([&- BN97\*K+#MTJRT M*X.[^1F*X"C77@2Z&?9 L-?2" )W8TX,8*^I7?[ZEWJTE\4B$X;D_.HWT[*6 M&5O,8T(8CA$$.L(Q($D, 4LB :!," U%0D*N!C>7.^%/W5H^"@8;18>^TH'=VX-9:\)OW9R-]QTS62OE58KV;_*':+SXKLJW_)553)1&7Y4 MI)66 '-L>D9F2.("$=,]8I'$2&K*\5!^6I%/C$ZM%7S;J/UO.#=M_X>1\7;E M1LM@0TZH=&[>BY)VI,D Z32PS4;W @\L;*TJ%:LG:XIIG0A"@(@C# CA">"Q MC$'"XSB,4DF2*!Q,Q5;@4T-1=S1&RW'8V/(^@ A/1XY ##/CAD/'SOUHV XT M'0P=VV^QT/5]=Q3>+E4N[7O7[Q?L:BXX0S&+%< 11("$"014,FDZ+((1P0I) M-GB^T(I\8A@>M0(K-AR&MOO#-'A[X'O MA?\EN[^0)EBFL^9(PL?;)5?E'*<")0AQ( @RE_\<*< 43$&4$D4A3%D<#9YP M[U6:9@A@Q(.V>M#(NPX"^O(U=!QPA"QX#07<$^ Q&#A@;L1XH"_RQ$." P9W M1P6'?L"CDC7#ATOSD[\62Y;E\S22YOHFAH9-:5&E$>"[R!V@RY+9$XY?'Y:\6,P)2[&6B0 J1 P03 PW-"4 0ZJ5A"FEP]_);44^ M,3AKK: 1&TY,V_UA6KP]N9$RT(X3(IU;]\*C'6DR-#H-;&/1O<"W%?RBKC([ M<\BK^OW\-.:*QI$"4&L(2(Q2D")H&D)$&3>73U(H[=8!M@6F:?Q^:#J><>C, MR= NS]^I5W,WU*1'2]?M9$0G]R3@Q U&.X).QF,AZUM(SE@M??AHZ4JKTP) M_7=9W%771N6&Y0]S*"-,TX0"EG!#IM($I&FH@<)2Z\C4/],Q.IX_ZM*9I@)N MI(-&.UB+.Y]"ZLS4T((XVK]7772U[G,<:9^Q,2>2.N-.?2AIG[F.FZ0+]GBPD!__Q_U,(\HY9 P!F"88'/%EBI 0P@!CQ61H>94Z]0-SB<*TV"Y M%@UJU<#(N@+Y-"]#41SAU@O"X48]\.LQ,P*\IQ$G1J['T"YL?0M],7N?+=1Z MEAUKD:(H@H 1P@#1U%SY$6& PY! I930>/ !I*?!IX'+ZGD.^+?R,)0H/W=> M, TQYH'1KH,1!&T%FQB>71N[W'2L&7EHMOZPR:?R8;V:;J&4C8^"5[$>?CW M/U+;8V[\N=JG@9_G<&V/O=X3MGWK1X]A+E:K6U5N3QEPC$,EH0:IM.]W0P8! MI1("E'!)M8QC+@9_?O.0V-0CF68#QYG,[&;.>3XS*A\CIS0NJ1@SK.GU>(R1 MS6[PYQK<]-K<,[[I_YF1=7C]UX#&E+._A6/T-K>8=3+'O3=1C08R7!C5%__TZ0#C'GQ>G> MP).A.L3>-JV#UA\%V$O&%VH>0PJ9X!'0/+*?13-EE,K(OAU"0R$8HBP>?%*Z M3^190*V5QS':9,B+3V??QV#S@.6Q6+8\'0O))NASXMBR=0#%]MJ1[>SG8E6Q MQ7^SF_HC+$F28A5&%'!L0=1(V=,X&H2$J@AC$B6QXVF<+IF)&]I&.S#B7K<2 MZDR48T/K;7]<1SO4N7]#VVEL?$?;#OL\+6VGM=Z>MGNU.YQ_E%E5J=Q>RM[F MZ]/=HTPF[O5:\B.N..!EL>PUM<[9_X?'&.6A.J$AAK$V]0R@U%XTZ M =1TGP!1S@B$E% %>/'.6C$.,?)_1''.?N,'V6<@XY7_%I1 MGWV<@PZ6OL[%[EC:NQ4O/E\7^>:-<1T9Y@2C]B.!RA8]!GB21 !&"49"(TR$ M'$KCT^ GAK"6"VH]YP,".WDX3-L8=VZ0.1ASPJK/@1=-.\$F@ZC/QC8[O6O\ M[QH)$;_,*CM("5,D4J( 8P@!DE ->"HDB+!.I8ZP4G P,D^#GQB96B,H= #1 M/_@_@XVZ^^TB'Y-QF)LQ%MVX<77G=9_(IS9&W2/R,=CD]X=\:J/KWI [:]SA M>5^42U6NB]=OJGZI)6DJ)36%)D6*V/D' Q32"+ HE9$2)(0,#N6G(_Z)$6H4 M-XW/<'*Z,G$8GI'^W/AI6PN^-7I'&C/N<>*%4%>\R2C:8V8;I'W+_"?[C[>I M_Y55:IX(@122! @([8VQ;"O'2 0DLK=[( REW'FLWU*8:J;?B 9&-;"R[O/\ M=EZ&#_.]W7I.\H<:]9KB=YH9-<)O1YQ\?M]IJ&MXW[W0'S/["?5Y3*&DC"!@ M6CT*B/VL B,2 P@UU@D*M;E*B^.G M?+NAGV?4UVNQ=][7_Q-](&__9CZ8K]Z\V#R2-?^OV)L7_P=02P,$% @ M33@"6?+(PIL/" &$$ !4 !R<&ED+3(P,C0P.# R7W!R92YX;6S5F]MN MW#@2AN_S%+W>VZ6;YT.09)#U) MCDXF1>#"#O1%X*-I"NB5#+[^\>O;LQ=\(^?.?']\M?JWC^1JJ=G'0@&\A+2[*]G31GL+BC[KY7'[Q MBZ.5;W/=K EYU9]V4)]=->7):;O@E,O;9K>_-L^-M39R3PF5PA*II"!.4$>8 M2X(*K253]A\GSR,HIC0DDI(Q1&:=26!)$"$YBY;RY)3K+[HJJ\_/NY?@-[! M]ZI-__7EWFG;GCU?+B\N+O8O0[/:KYN3):=4+&];[]TTO[S7_D+TK9ES;MG_ M^K7IIGRH(5Z6+?]\_^Y3/(6U)V6U:7T5.P.;\OFF/_BNCK[M5?^?_5H\VJ+[ M1FZ;D>X089P(MG^Y27NOGBT6UW(T]0H^0EYT[[]_//QJLO%G95J7L:E#6>_' M>KWL6BP/:B3BR)]T_>W/;Z_.X.7>IER?K;X>.VT@O]QK\ *D&UB*8]!9_?NW MDY??.G#6P :IZ1U^AP=NKM%9>V)GX+*%*L&UE[=F5G6\TVC5:5PWMV>N?(!5 M?[1(4!;]E5^'3=OXV!:6!4DAHWI)""*YC\1S"(1Y",%GYS+\X'O7[PUVO!^2 M#<3]D_K+$B^\[/3H/O3"]*+<,WNS#"HK (4J(D6BJ M$I%4*!)2%B09[;.-WC&O1[GPF.6[WGP_V*^;N*B;! T&EUO3OHEW!OX^UC^P0N1>%JNTNW9N:G74XQA6T^LZ/708=?W%JA AJ:!].YZY!YUM/>RQ? + M?IT2JK^!S,C+?=?W7>NW+"C6QP;-HB ;'"4[(BGB3*5': M"V7 1V'B*$KNF=P>&%..8SV5J%LFXBW>(AA/KUUX#^L 3>$H!P;@"!<.[Y., M"5K0/!/0'J0WT@DS;E9YP.CVJ!@Y?/5T6FX9A0?B)F9N<-C">E-PJI06,1 G M R-2!T-\P%#J?%*9F2P-4U-G&E^M#X*#SV(NF4SD'8&ENVT*KV,P/&04 TF7 M.6"7+0U$I:BIQMB9!)L$CL[:3B463QR[!X#XRT+N" !'T)1U>E.E7WV+MX6/ M.G&C2,J BW:<,HEEG!(ALN>8F2L /@D)=\SN5'R8#HFG2[L3*Y./<%)VR[2J M_2#)YD;360(B3@#B+I65)CD?=!N@O7(7:N#R!"S(6.TL#L!QF$5 MZ^:L;GI1/N%PP$%]7K7-U4&=H !*#541(^>&2I1*!,YL%M)-PENNX+?S/LFV&@*-2A&=.:[<1&0D>".(3"EBC,R"9SH! M,M\L#N)#S8R/)PJZ$S <^\O#A+*4N;PNLM\X(F2FU@$GG@J,C8H9XH+D1 L0 MG%KFJ)83D/&(^4&8Z)EA,H74.\',S4+]YJV3AQ7H.B[@:"0V:8NXJTQLEX]C M>I6=X&"4%Q/P\H#I0:R8F;$R5N(=Y807VD33/88D(N?N&6;.)/" LR6$:# 1 M#\J->W;TJ.E!G-C9<_+7)-XE3@[PXX?FN+ZH"JJD5"!Q\I2N(83T2:H(@5 MR'PR,8H,F(>Q-?'2!L)B-C8Z&YFSH^CXWMHP'N93>GVRDELFH-M;MCHZK:O;%;R2+/"H M@7AC,I&8:V.D4XRD$*@Q5/@8Q\6('RT.(V$^I=91BFZ9AC^:LFVA.JC7Z_/J M9I6^*4)6FEN&2M#H<>%ET0'/,*H9EC&C%C&/+, _:'88%_.II8[7=LMP?*I7 M92S;LCIYC\E14_I5D05W2FM%LE.<2(=++:M(2/T#AC@ MJDM+F8(WSHU+5'^T.(R.^5101RFZ91J.&]_]\>C3U3K4JX(*HQ6GEF23 I%4 M6YPP 06!Y%,.P#(?EZ#>,3>,@_E429^NY8Z$A#>7\=17)]!O:HD\YQ"X($S@ MK"@U+KF<38:DG% 6+5,2XS:2/61UV#ZR^=1"1RN[$S70-VMH3I#L?S7U17N* M,^&9KZX*@Z',"1%(HDX1R:/H-FD[DA1+"JSE3)I1@/S$^#!.YE8%':_S;N!R MB9&PVI2=--<[* LI<7$NA"0NA2X_,JDKXABB-$Z:P)---D_!RCW+PT"93WET M$H5W@I(#E*;QJT-,HB__#5=%]\20*V!$)2Z)C-JC \)BTF2C--GS:*?8=?B# MV6%\S*=H.E[;;?]!#B5)G2QO5_ZD"+@JI[93@ H@4D5-O&4.Y\M@!34NC:V8 MWC$W#(;Y5$J?KN5D$+Q8WM,2_?K\ZMG-#]U+]T?Z5\_^"U!+ 0(4 Q0 ( M $TX EE=&RUMYAT +2G 0 > " 0 !R<&ED+3(P,C0P M-C,P>&5X>#DY,7@R,#(T,"YH=&U02P$"% ,4 " !-. )9SIMR1@H: #Z MD@ $0 @ $B'@ U0( :/@ %0 M @ $).P &UL4$L! A0#% @ M33@"674D_C^(# )VX !4 ( !D$, ')P:60M,C R-# X M,#)?;&%B+GAM;%!+ 0(4 Q0 ( $TX EGRR,*;#P@ !A! 5 M " 4M0 !R<&ED+3(P,C0P.# R7W!R92YX;6Q02P4& 8 !@"3 ) 0 C5@ end XML 17 rpid-20240802_htm.xml IDEA: XBRL DOCUMENT 0001380106 2024-08-02 2024-08-02 0001380106 dei:FormerAddressMember 2024-08-02 2024-08-02 0001380106 false 8-K 2024-08-02 RAPID MICRO BIOSYSTEMS, INC. DE 001-40592 20-8121647 25 Hartwell Avenue, Lexington, MA 02421 978 349-3200 1001 Pawtucket Boulevard West Suite 280 Lowell MA 01854 false false false false Class A Common Stock, $0.01 par value per share RPID NASDAQ true false